Early benefit assessment reveals weaknesses in the development of new drugs

11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...

Read more →

New drugs: where did we go wrong and what can we do better?

10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...

Read more →

Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods

10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...

Read more →

Negotiating drug prices without restricting patient access: lessons from Germany

27 June 2019 - In the ongoing conversation about high drug prices in the United States, some loud voices argue ...

Read more →

German patients get the latest drugs for just $11. Can such a model work in the U.S.?

19 June 2019 - Patients who come to the Havelhöhe cancer clinic in the leafy outskirts of Germany’s capital are ...

Read more →

UK, Germany, dissociate from WHO drug pricing resolution

8 June 2019 - The passage of a landmark resolution on improving the transparency of markets for medicines at the latest ...

Read more →

Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma

15 May 2019 - There are no serious disadvantages in terms of overall survival. ...

Read more →

Apalutamide in prostate cancer: indication of significant added benefit

2 May 2019 - Study shows significant slowing of symptomatic progression. ...

Read more →

Ribociclib in advanced breast cancer: survival benefits, but also severe side effects

15 April 2019 - In the overall view, an added benefit is not proven. ...

Read more →

Numerous G-BA decisions on new medicines - five active substances with considerable added value

22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the ...

Read more →

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →

Germany agrees on new pharmaceutical bill

13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...

Read more →

Erenumab in migraine: indication of a significant added benefit for certain patients

2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...

Read more →

Citizens ask - scientists answer: the IQWiG sets four new topics for HTA reports

23 January 2019 - Citizens, patients and medical experts: selection of topics with a sense of proportion ...

Read more →

Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival

15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...

Read more →